deals
制药,Artificial Intelligence,生物制药
Harvard spinout Nabla Bio lands $11M to bring AI technology to antibody design
Nabla Bio去年从著名的哈佛大学乔治教堂的实验室出现了，其抗体发现技术已经导致了与制药和生物技术公司建立五个合作伙伴关系。这家初创公司仅关闭了1100万美元的种子融资，这将支持其技术的进一步发展。
Biotech startup AviadoBio emerges with $80M for neuro disorder gene therapies
Aviadobio的基因疗法旨在在整个中枢神经系统中实现广泛的分布。该公司的领先计划正在开始进行人体测试，以作为额颞痴呆的治疗方法。
神经科学的新兴黄金时代
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.
Omnicell以1亿美元的接收并购交易进入了种植专业药房空间
Specialty drugs represent a growing share of overall pharmaceutical sales, and Omnicell is acquiring specialty pharmacy technologies company ReCept Pharmacy to enter this market. Omnicell is paying $100 million cash to buy ReCept.
诺华通过在UCB Parkinson的毒品上联盟来增强神经管道
诺华正在提前支付UCB $ 1.5亿美元，以开发两种临床帕金森氏病药物，这些药物为治疗这种疾病提供了新的方法。根据这些药物的进度，UCB最高可赚取15亿美元的里程碑付款。
Sanofi makes another mRNA move with deal for skin microbiome biotech Origimm
赛诺菲的策略开发新信使RNA vaccines is adding another piece. The pharmaceutical giant struck a deal to acquire Origimm Biotechnology, a startup developing therapeutic vaccines to treat skin diseases and infections.
Cell therapy biotech Quell adds $156M for alternative to organ transplant meds
Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress is part of a growing field of Treg cell therapy developers that is becoming increasingly competitive.
蓝图药物购买具有巨大优势的癌症药物初创企业，J＆J针对性疗法
Blueprint药物预先支付2.5亿美元，以获取目标癌症疗法的开发商Lengo Therapeutics。这家初创公司的主要药物候选人正开通非小细胞肺癌的人体测试，蓝图认为，小分子比Johnson＆Johnson和Takeda Pharmaceutical的新靶向疗法具有优势。
GSK加入纳什·蔡斯（Nash Chase），支付1.2亿美元，以支付Arrowhead RNAi Drug的权利
GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for rights to the experimental therapy. The Arrowhead drug uses RNA interference to “silence” an enzyme associated with the progression of the fatty liver disease.
-
狗万1.0
AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 million to license the rights to these preclinical and clinical-stage compounds that address muscarinic receptors to potentially treat a range of neurological disorders.
Vifor Pharma通过一对收购增加了慢性肾脏疾病阵容
肾脏学产品公司Vifor Pharma正在炮击约2.52亿美元，以获取Sanifit Therapeutics和Inositec，这是影响某些慢性肾脏疾病患者的血管并发症的药物开发者。两种生物技术都在临床试验中，其各自的铅候选药物。
赛诺菲（Sanofi）的2.7亿美元下注，一家初创公司的AI技术可以增强其癌症药物研发
The sum represents Sanofi’s equity investment in Owkin, plus a payment to begin a research partnership covering four types of cancer. Meanwhile, Owkin said the Sanofi investment boosts the startup into unicorn status and marks the start of its Series B funding round.
Generate Bio adds $370M for big push toward programmable protein medicines
Generate Biomedicines applies artificial intelligence and machine learning to protein analysis, which it uses to program its protein therapies for particular applications. The startup now has $370 million in financing to rapidly scale up operations, with a goal of reaching the clinic within two years.
Novo Nordisk达到$ 3.3B交易，以获取RNAi合作伙伴Dicerna Pharma
收购协议恰好是两年后，两家公司开始建立广泛的联盟，致力于为代谢疾病开发RNA干扰药物。该联盟最先进的疗法有望在2022年到达诊所。
Organon makes another women’s health move with deal for endometriosis-focused Forendo
Organon’s proposed acquisition of Forendo Pharma is the company’s third since spinning out of Merck in the summer. Clinical-stage Forendo is developing a new, potentially more targeted approach to treating endometriosis.
Biohaven的偏头痛进度与两种毒品的辉瑞营销协定有关
Biohaven Pharmaceuticals has seen strong U.S. market uptake for its oral migraine drug, Nurtec. With regulatory decisions looming around the world, the company has landed the marketing muscle of Pfizer, which is paying $500 million up front for the right to market that drug and another clinical-stage compound outside of the U.S.
Promoted
Promoted
重新构想医疗保健：转变云中的医疗保健
Learn how healthcare organizations are working withMicrosoftto enhance patient engagement, accelerate healthcare innovation, support collaboration, improve clinical and operational insights and transform healthcare in the cloud.
